Daniel P Judge

List of Publications by Year
in descending order

210 papers	27,293 citations	7551 77 h-index	5965 160 g-index
216 all docs	216 docs citations	216 times ranked	19051 citing authors

#	Article	IF	Citations
1	Losartan, an AT1 Antagonist, Prevents Aortic Aneurysm in a Mouse Model of Marfan Syndrome. Science, 2006, 312, 117-121.	6.0	1,591
2	Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. New England Journal of Medicine, 2018, 379, 1007-1016.	13.9	1,558
3	A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nature Genetics, 2005, 37, 275-281.	9.4	1,543
4	Marfan's syndrome. Lancet, The, 2005, 366, 1965-1976.	6.3	1,021
5	HRS/EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies. Heart Rhythm, 2011, 8, 1308-1339.	0.3	995
6	Angiotensin II Blockade and Aortic-Root Dilation in Marfan's Syndrome. New England Journal of Medicine, 2008, 358, 2787-2795.	13.9	767
7	HRS/EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies: This document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Europace, 2011, 13, 1077-1109.	0.7	699
8	Angiotensin II type 1 receptor blockade attenuates TGF-Î²â€“induced failure of muscle regeneration in multiple myopathic states. Nature Medicine, 2007, 13, 204-210.	15.2	603
9	Exercise Increases Age-Related Penetrance and Arrhythmic Risk in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathyâ€“Associated Desmosomal Mutation Carriers. Journal of the American College of Cardiology, 2013, 62, 1290-1297.	1.2	553
10	2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy. Heart Rhythm, 2019, 16, e301-e372.	0.3	494
11	Studying arrhythmogenic right ventricular dysplasia with patient-specific iPSCs. Nature, 2013, 494, 105-110.	13.7	474
12	TGF-Î²â€“dependent pathogenesis of mitral valve prolapse in a mouse model of Marfan syndrome. Journal of Clinical Investigation, 2004, 114, 1586-1592.	3.9	467
13	Arrhythmogenic Right Ventricular Dysplasia. Circulation, 2005, 112, 3823-3832.	1.6	434
14	Noncanonical TGFÎ² Signaling Contributes to Aortic Aneurysm Progression in Marfan Syndrome Mice. Science, 2011, 332, 358-361.	6.0	422
15	Angiotensin II Type 2 Receptor Signaling Attenuates Aortic Aneurysm in Mice Through ERK Antagonism. Science, 2011, 332, 361-365.	6.0	414
16	Clinical Presentation, Long-Term Follow-Up, and Outcomes of 1001 Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy Patients and Family Members. Circulation: Cardiovascular Genetics, 2015, 8, 437-446.	5.1	370
17	Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: evidence supporting the concept of arrhythmogenic cardiomyopathy. European Journal of Heart Failure, 2012, 14, 1199-1207.	2.9	369
18	Impact of genotype on clinical course in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated mutation carriers. European Heart Journal, 2015, 36, 847-855.	1.0	338

#	Article	IF	Citations
19	Genotype and Phenotype of Transthyretin Cardiac Amyloidosis. Journal of the American College of Cardiology, 2016, 68, 161-172.	1.2	338
20	Evidence for a critical contribution of haploinsufficiency in the complex pathogenesis of Marfan syndrome. Journal of Clinical Investigation, 2004, 114, 172-181.	3.9	319
21	Missense Mutations in Plakophilin-2 Cause Sodium Current Deficit and Associate With a Brugada Syndrome Phenotype. Circulation, 2014, 129, 1092-1103.	1.6	305
22	TGF-Î²â€“dependent pathogenesis of mitral valve prolapse in a mouse model of Marfan syndrome. Journal of Clinical Investigation, 2004, 114, 1586-1592.	3.9	303
23	Arrhythmogenic Cardiomyopathy. Circulation Research, 2017, 121, 784-802.	2.0	294
24	Mitral valve diseaseâ€”morphology and mechanisms. Nature Reviews Cardiology, 2015, 12, 689-710.	6.1	281
25	Genetic Evaluation of Cardiomyopathyâ€”A Heart Failure Society of America Practice Guideline. Journal of Cardiac Failure, 2018, 24, 281-302.	0.7	280
26	Distinguishing Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasiaâ€“Associated Mutations From Background Genetic Noise. Journal of the American College of Cardiology, 2011, 57, 2317-2327.	1.2	269
27	Contemporary Cardiac Issues in Duchenne Muscular Dystrophy. Circulation, 2015, 131, 1590-1598.	1.6	240
28	Arrhythmogenic right ventricular cardiomyopathy: evaluation of the current diagnostic criteria and differential diagnosis. European Heart Journal, 2020, 41, 1414-1429.	1.0	239
29	Long-Term Efficacy of Catheter Ablation of Ventricular Tachycardia in Patients With Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. Journal of the American College of Cardiology, 2007, 50, 432-440.	1.2	236
30	Incidence and Predictors of Implantable Cardioverter-Defibrillator Therapy in Patients With Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy Undergoing Implantable Cardioverter-Defibrillator Implantation for Primary Prevention. Journal of the American College of Cardiology, 2011, 58, 1485-1496.	1.2	226
31	KLOTHO Allele Status and the Risk of Early-Onset Occult Coronary Artery Disease. American Journal of Human Genetics, 2003, 72, 1154-1161.	2.6	225
32	Clinical Features of Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy Associated With Mutations in Plakophilin-2. Circulation, 2006, 113, 1641-1649.	1.6	225
33	Evidence for a critical contribution of haploinsufficiency in the complex pathogenesis of Marfan syndrome. Journal of Clinical Investigation, 2004, 114, 172-181.	3.9	225
34	Identification of a New Modulator of the Intercalated Disc in a Zebrafish Model of Arrhythmogenic Cardiomyopathy. Science Translational Medicine, 2014, 6, 240ra74.	5.8	222
35	Angiotensin IIâ€“dependent TGF-Î² signaling contributes to Loeys-Dietz syndrome vascular pathogenesis. Journal of Clinical Investigation, 2014, 124, 448-460.	3.9	214
36	Evidence-Based Assessment of Genes in Dilated Cardiomyopathy. Circulation, 2021, 144, 7-19.	1.6	213

#	Article	IF	Citations
37	Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: The Transthyretin Amyloidosis Cardiac Study (TRACS). American Heart Journal, 2012, 164, 222-228.e1.	1.2	209
38	Mechanisms of Disease: molecular genetics of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Nature Clinical Practice Cardiovascular Medicine, 2008, 5, 258-267.	3.3	207
39	DSG2 Mutations Contribute to Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. American Journal of Human Genetics, 2006, 79, 136-142.	2.6	206
40	Comprehensive Desmosome Mutation Analysis in North Americans With Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. Circulation: Cardiovascular Genetics, 2009, 2, 428-435.	5.1	195
41	Loss of Elastic Fiber Integrity and Reduction of Vascular Smooth Muscle Contraction Resulting From the Upregulated Activities of Matrix Metalloproteinase-2 and -9 in the Thoracic Aortic Aneurysm in Marfan Syndrome. Circulation Research, 2007, 101, 512-522.	2.0	193
42	Management of Cardiac Involvement Associated With Neuromuscular Diseases: A Scientific Statement From the American Heart Association. Circulation, 2017, 136, e200-e231.	1.6	189
43	Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs. Heart Failure Reviews, 2015, 20, 163-178.	1.7	178
44	Outcomes of Catheter Ablation of Ventricular Tachycardia in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. Circulation: Arrhythmia and Electrophysiology, 2012, 5, 499-505.	2.1	175
45	Genetic evaluation of cardiomyopathy: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). Genetics in Medicine, 2018, 20, 899-909.	1.1	172
46	Transthyretin Stabilization by AG10 in Symptomatic Transthyretin AmyloidÂCardiomyopathy. Journal of the American College of Cardiology, 2019, 74, 285-295.	1.2	170
47	Exercise has a Disproportionate Role in the Pathogenesis of Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy in Patients Without Desmosomal Mutations. Journal of the American Heart Association, 2014, 3, e001471.	1.6	158
48	Mutationâ€Positive Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy: The Triangle of Dysplasia Displaced. Journal of Cardiovascular Electrophysiology, 2013, 24, 1311-1320.	0.8	148
49	Multilevel analyses of SCN5A mutations in arrhythmogenic right ventricular dysplasia/cardiomyopathy suggest non-canonical mechanisms for disease pathogenesis. Cardiovascular Research, 2017, 113, 102-111.	1.8	148
50	Genetic Testing for Dilated Cardiomyopathy in Clinical Practice. Journal of Cardiac Failure, 2012, 18, 296-303.	0.7	145
51	The diagnosis of hypertrophic cardiomyopathy by cardiovascular magnetic resonance. Journal of Cardiovascular Magnetic Resonance, 2012, 14, 12.	1.6	141
52	Endomyocardial Biopsy Characterization of HeartÂFailure With Preserved EjectionÂFraction and Prevalence of Cardiac Amyloidosis. JACC: Heart Failure, 2020, 8, 712-724.	1.9	138
53	2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy: Executive summary. Heart Rhythm, 2019, 16, e373-e407.	0.3	135
54	Central role for GSK3Î² in the pathogenesis of arrhythmogenic cardiomyopathy. JCI Insight, 2016, 1, .	2.3	127

#	Article	IF	Citations
55	Therapeutic Modulation of the Immune Response in Arrhythmogenic Cardiomyopathy. Circulation, 2019, 140, 1491-1505.	1.6	127
56	Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis. Neurology and Therapy, 2016, 5, 1-25.	1.4	124
57	Penetrance of Mutations in Plakophilin-2 Among Families With Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. Journal of the American College of Cardiology, 2006, 48, 1416-1424.	1.2	122
58	Effects of Tafamidis on Transthyretin Stabilization and Clinical Outcomes in Patients with Non-Val30Met Transthyretin Amyloidosis. Journal of Cardiovascular Translational Research, 2013, 6, 1011-1020.	1.1	122
59	Short-Term Effects of Right-Left Heart Sequential Cardiac Resynchronization in Patients With Heart Failure, Chronic Atrial Fibrillation, and Atrioventricular Nodal Block. Circulation, 2004, 110, 3404-3410.	1.6	120
60	Current treatment of adult Duchenne muscular dystrophy. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2007, 1772, 229-237.	1.8	120
61	Epidemiology of the inherited cardiomyopathies. Nature Reviews Cardiology, 2021, 18, 22-36.	6.1	117
62	Incremental Value of Cardiac Magnetic Resonance Imaging in Arrhythmic Risk Stratification of Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathyâ€“Associated Desmosomal Mutation Carriers. Journal of the American College of Cardiology, 2013, 62, 1761-1769.	1.2	112
63	Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy and Cardiac Sarcoidosis. Circulation: Arrhythmia and Electrophysiology, 2014, 7, 230-236.	2.1	112
64	International Evidence Based Reappraisal of Genes Associated With Arrhythmogenic Right Ventricular Cardiomyopathy Using the Clinical Genome Resource Framework. Circulation Genomic and Precision Medicine, 2021, 14, e003273.	1.6	112
65	Allelic variation in normal human FBN1 expression in a family with Marfan syndrome: a potential modifier of phenotype?. Human Molecular Genetics, 2003, 12, 2269-2276.	1.4	110
66	Tafamidis in Transthyretin Amyloid Cardiomyopathy. Circulation: Heart Failure, 2015, 8, 519-526.	1.6	110
67	Efficacy and safety of tafamidis doses in the <scp>Tafamidis in Transthyretin Cardiomyopathy Clinical Trial</scp> (<scp>ATTRâ€ACT</scp>) and longâ€term extension study. European Journal of Heart Failure, 2021, 23, 277-285.	2.9	103
68	Outcomes and ventricular tachycardia recurrence characteristics after epicardial ablation of ventricular tachycardia in arrhythmogenic right ventricular dysplasia/cardiomyopathy. Heart Rhythm, 2015, 12, 716-725.	0.3	101
69	Arrhythmogenic cardiomyopathy: pathology, genetics, and concepts in pathogenesis. Cardiovascular Research, 2017, 113, 1521-1531.	1.8	98
70	Regional Variation in RBM20 Causes a Highly Penetrant Arrhythmogenic Cardiomyopathy. Circulation: Heart Failure, 2019, 12, e005371.	1.6	96
71	Risk Stratification in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathyâ€“Associated Desmosomal Mutation Carriers. Circulation: Arrhythmia and Electrophysiology, 2013, 6, 569-578.	2.1	94
72	Neonatal Transplantation Confers Maturation of PSC-Derived Cardiomyocytes Conducive to Modeling Cardiomyopathy. Cell Reports, 2017, 18, 571-582.	2.9	90

#	Article	IF	Citations
73	Electrocardiographic Features of Arrhythmogenic Right Ventricular Dysplasia. Circulation, 2009, 120, 477-487.	1.6	88
74	Yield of Serial Evaluation in At-Risk Family Members of Patients With ARVD/C. Journal of the American College of Cardiology, 2014, 64, 293-301.	1.2	88
75	A deleterious gene-by-environment interaction imposed by calcium channel blockers in Marfan syndrome. ELife, 2015, 4, .	2.8	87
76	Morphologic Variants of Familial Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. Journal of the American College of Cardiology, 2009, 53, 1289-1299.	1.2	84
77	Definition and treatment of arrhythmogenic cardiomyopathy: an updated expert panel report. European Journal of Heart Failure, 2019, 21, 955-964.	2.9	84
78	Long-term safety and efficacy of tafamidis for the treatment of hereditary transthyretin amyloid polyneuropathy: results up to 6 years. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 194-204.	1.4	83
79	Sudden Cardiac Death Prediction in Arrhythmogenic Right Ventricular Cardiomyopathy. Circulation: Arrhythmia and Electrophysiology, 2021, 14, e008509.	2.1	82
80	Recessive arrhythmogenic right ventricular dysplasia due to novel cryptic splice mutation inPKP2. Human Mutation, 2006, 27, 1157-1157.	1.1	77
81	Cardiac Management of the Patient With Duchenne Muscular Dystrophy. Pediatrics, 2018, 142, S72-S81.	1.0	77
82	Cardiac Transplantation in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. Journal of the American College of Cardiology, 2012, 59, 289-290.	1.2	76
83	Right ventricular afterload sensitivity dramatically increases after left ventricular assist device implantation: A multi-center hemodynamic analysis. Journal of Heart and Lung Transplantation, 2016, 35, 868-876.	0.3	76
84	Safety of American Heart Association-recommended minimum exercise for desmosomal mutation carriers. Heart Rhythm, 2016, 13, 199-207.	0.3	76
85	Role of Genetic Testing in Inherited Cardiovascular Disease. JAMA Cardiology, 2017, 2, 1153.	3.0	75
86	The benefit of upgrading chronically right ventricleâ€“paced heart failure patients to resynchronization therapy demonstrated by strain rate imaging. Heart Rhythm, 2006, 3, 435-442.	0.3	74
87	Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy in the PediatricÂPopulation. JACC: Clinical Electrophysiology, 2015, 1, 551-560.	1.3	74
88	Utility of Tissue Doppler and Strain Echocardiography in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. American Journal of Cardiology, 2007, 100, 507-512.	0.7	73
89	Pathophysiology and Therapy of Cardiac Dysfunction in Duchenne Muscular Dystrophy. American Journal of Cardiovascular Drugs, 2011, 11, 287-294.	1.0	73
90	Sildenafil does not improve cardiomyopathy in <scp>D</scp>uchenne/<scp>B</scp>ecker muscular dystrophy. Annals of Neurology, 2014, 76, 541-549.	2.8	73

#	Article	IF	Citations
91	Prevalence of atrial arrhythmias in arrhythmogenic right ventricular dysplasia/cardiomyopathy. Heart Rhythm, 2013, 10, 1661-1668.	0.3	71
92	Variant Interpretation for Dilated Cardiomyopathy. Circulation Genomic and Precision Medicine, 2020, 13, e002480.	1.6	70
93	Angiotensin II antagonism is associated with reduced risk for gastrointestinal bleeding caused by arteriovenous malformations in patients with left ventricular assist devices. Journal of Heart and Lung Transplantation, 2017, 36, 380-385.	0.3	69
94	Seven factors predict a delayed diagnosis of cardiac amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2018, 25, 174-179.	1.4	69
95	Approach to family screening in arrhythmogenic right ventricular dysplasia/cardiomyopathy. European Heart Journal, 2016, 37, 755-763.	1.0	68
96	Implantable Cardioverterâ€Ðefibrillator Therapy in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy: Predictors of Appropriate Therapy, Outcomes, and Complications. Journal of the American Heart Association, 2017, 6, .	1.6	68
97	Mutations in AlstrÃ¶m protein impair terminal differentiation of cardiomyocytes. Nature Communications, 2014, 5, 3416.	5.8	66
98	Genetic and Phenotypic Landscape of Peripartum Cardiomyopathy. Circulation, 2021, 143, 1852-1862.	1.6	65
99	Exercise Testing in Asymptomatic Gene Carriers Exposes a Latent Electrical Substrate of Arrhythmogenic Right Ventricular Cardiomyopathy. Journal of the American College of Cardiology, 2013, 62, 1772-1779.	1.2	64
100	Cardiac Findings and Events Observed in an Open-Label Clinical Trial of Tafamidis in Patients with non-Val30Met and non-Val122Ile Hereditary Transthyretin Amyloidosis. Journal of Cardiovascular Translational Research, 2015, 8, 117-127.	1.1	61
101	Cutaneous nerve biomarkers in transthyretin familial amyloid polyneuropathy. Annals of Neurology, 2017, 82, 44-56.	2.8	61
102	Therapy of Marfan Syndrome. Annual Review of Medicine, 2008, 59, 43-59.	5.0	56
103	Plasma BIN1 correlates with heart failure and predicts arrhythmia in patients with arrhythmogenic right ventricular cardiomyopathy. Heart Rhythm, 2012, 9, 961-967.	0.3	56
104	The TMEM43 Newfoundland mutation p.S358L causing ARVC-5 was imported from Europe and increases the stiffness of the cell nucleus. European Heart Journal, 2015, 36, 872-881.	1.0	56
105	Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR). Cardiovascular Drugs and Therapy, 2020, 34, 357-370.	1.3	55
106	Evaluation of Structural Progression in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. JAMA Cardiology, 2017, 2, 293.	3.0	53
107	Heart Failure Is Common and Under-Recognized in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia. Circulation: Heart Failure, 2017, 10, .	1.6	53
108	Hypermobile <scp>Ehlersâ€Ðanlos</scp> syndromes: Complex phenotypes, challenging diagnoses, and poorly understood causes. Developmental Dynamics, 2021, 250, 318-344.	0.8	53

#	Article	IF	Citations
109	Relationship between monoclonal gammopathy and cardiac amyloid type. Cardiovascular Pathology, 2013, 22, 189-194.	0.7	52
110	Conductance catheter-based assessment of arterial input impedance, arterial function, and ventricular-vascular interaction in mice. American Journal of Physiology - Heart and Circulatory Physiology, 2005, 288, H1157-H1164.	1.5	51
111	Toward an Understanding of Dural Ectasia: A Light Microscopy Study in a Murine Model of Marfan Syndrome. Spine, 2005, 30, 291-293.	1.0	50
112	Use of Genetics in the Clinical Evaluation of Cardiomyopathy. JAMA - Journal of the American Medical Association, 2009, 302, 2471.	3.8	50
113	Pregnancy course and outcomes in women with arrhythmogenic right ventricular cardiomyopathy. Heart, 2016, 102, 303-312.	1.2	50
114	Etiology of limb girdle muscular dystrophy 1D/1E determined by laser capture microdissection proteomics. Annals of Neurology, 2012, 71, 141-145.	2.8	49
115	Malignant Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy with a normal 12-lead electrocardiogram: A rare but underrecognized clinical entity. Heart Rhythm, 2013, 10, 1484-1491.	0.3	47
116	Cardiac phenotype and long-term prognosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia patients with late presentation. Heart Rhythm, 2017, 14, 883-891.	0.3	47
117	Exercise triggers CAPN1-mediated AIF truncation, inducing myocyte cell death in arrhythmogenic cardiomyopathy. Science Translational Medicine, 2021, 13, .	5.8	46
118	Mitral Valve Disease in Marfan Syndrome and Related Disorders. Journal of Cardiovascular Translational Research, 2011, 4, 741-747.	1.1	45
119	A Pkd1-Fbn1 Genetic Interaction Implicates TGF-Î² Signaling in the Pathogenesis of Vascular Complications in Autosomal Dominant Polycystic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2014, 25, 81-91.	3.0	44
120	Nonmyocyte ERK1/2 signaling contributes to load-induced cardiomyopathy in Marfan mice. JCI Insight, 2017, 2, .	2.3	44
121	FLNC truncations cause arrhythmogenic right ventricular cardiomyopathy. Journal of Medical Genetics, 2020, 57, 254-257.	1.5	43
122	Phenotypic Expression, Natural History, and Risk Stratification of Cardiomyopathy Caused by Filamin C Truncating Variants. Circulation, 2021, 144, 1600-1611.	1.6	43
123	Ankyrin-B dysfunction predisposes to arrhythmogenic cardiomyopathy and is amenable to therapy. Journal of Clinical Investigation, 2019, 129, 3171-3184.	3.9	42
124	Arrhythmogenic Right Ventricular Cardiomyopathy-Associated Desmosomal Variants Are Rarely De Novo. Circulation Genomic and Precision Medicine, 2019, 12, e002467.	1.6	38
125	The Change in B-Type Natriuretic Peptide Levels Over Time Predicts Significant Rejection in Cardiac Transplant Recipients. Journal of Heart and Lung Transplantation, 2009, 28, 704-709.	0.3	35
126	Characterizing the Molecular Pathology of Arrhythmogenic Cardiomyopathy in Patient Buccal Mucosa Cells. Circulation: Arrhythmia and Electrophysiology, 2016, 9, e003688.	2.1	35

#	Article	IF	Citations
127	Comparison of Features of Fatal Versus Nonfatal Cardiac Arrest in Patients With Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. American Journal of Cardiology, 2017, 120, 111-117.	0.7	35
128	A new prediction model for ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy. European Heart Journal, 2022, 43, e1-e9.	1.0	35
129	Prolonged RV endocardial activation duration: A novel marker of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Heart Rhythm, 2009, 6, 769-775.	0.3	32
130	Association of Common Variations on Chromosome 4q25 and Left Atrial Volume in Patients with Atrial Fibrillation. Clinical Medicine Insights: Cardiology, 2015, 9, CMC.S21712.	0.6	32
131	Reversible cardiomyopathy caused by administration of interferon Î±. Nature Clinical Practice Cardiovascular Medicine, 2005, 2, 53-57.	3.3	30
132	The Mitral Valve in Hypertrophic Cardiomyopathy. Journal of Cardiovascular Translational Research, 2011, 4, 757-766.	1.1	30
133	Transthyretin Cardiac Amyloidosis: Pathogenesis, Treatments, and Emerging Role in Heart Failure with Preserved Ejection Fraction. Clinical Medicine Insights: Cardiology, 2014, 8s1, CMC.S15719.	0.6	30
134	Drug Discovery and Development in Rare Diseases: Taking a Closer Look at the Tafamidis Story. Drug Design, Development and Therapy, 2021, Volume 15, 1225-1243.	2.0	29
135	Lack of Relationship Between Serum Cardiac Troponin I Level and Giant Cell Myocarditis Diagnosis and Outcomes. Journal of Cardiac Failure, 2016, 22, 583-585.	0.7	28
136	Tnni3k alleles influence ventricular mononuclear diploid cardiomyocyte frequency. PLoS Genetics, 2019, 15, e1008354.	1.5	28
137	Prevalence and Cumulative Risk of Familial Idiopathic Dilated Cardiomyopathy. JAMA - Journal of the American Medical Association, 2022, 327, 454.	3.8	28
138	Novel and Highly Lethal NKX2.5 Missense Mutation in a Family With Sudden Death and Ventricular Arrhythmia. Pediatric Cardiology, 2014, 35, 1206-1212.	0.6	26
139	ATTR Epidemiology, Genetics, and Prognostic Factors. Methodist DeBakey Cardiovascular Journal, 2022, 18, 17-26.	0.5	26
140	Genetic Evaluation of Familial Cardiomyopathy. Journal of Cardiovascular Translational Research, 2008, 1, 144-154.	1.1	25
141	LMNAâ€associated cardiocutaneous progeria: An inherited autosomal dominant premature aging syndrome with late onset. American Journal of Medical Genetics, Part A, 2013, 161, 1599-1611.	0.7	25
142	Spectrum of Biventricular Involvement on CMR Among Carriers of ARVD/C-Associated Mutations. JACC: Cardiovascular Imaging, 2015, 8, 863-864.	2.3	25
143	Genetic testing improves identification of transthyretin amyloid (ATTR) subtype in cardiac amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 92-95.	1.4	24
144	Familial Hypertrophic Cardiomyopathy Associated with Cardiac Î²-Myosin Heavy Chain and Troponin I Mutations. Pediatric Cardiology, 2008, 29, 846-850.	0.6	21

#	Article	IF	Citations
145	Shared Desmosome Gene Findings in Early and Late Onset Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. Journal of Cardiovascular Translational Research, 2010, 3, 663-673.	1.1	21
146	Cadherin 2-Related Arrhythmogenic Cardiomyopathy. Circulation Genomic and Precision Medicine, 2021, 14, e003097.	1.6	21
147	Protein molecular modeling techniques investigating novel <scp>TAB</scp>2 variant R347X causing cardiomyopathy and congenital heart defects in multigenerational family. Molecular Genetics & Genomic Medicine, 2018, 6, 666-672.	0.6	19
148	Multi-Scale Biomechanical Remodeling in Aging and Genetic Mutant Murine Mitral Valve Leaflets: Insights into Marfan Syndrome. PLoS ONE, 2012, 7, e44639.	1.1	18
149	Natural history and progression of transthyretin amyloid cardiomyopathy: insights from ATTRâ€ACT. ESC Heart Failure, 2021, 8, 3875-3884.	1.4	18
150	Performance of the 2015 International Task Force Consensus Statement Risk Stratification Algorithm for Implantable Cardioverter-Defibrillator Placement in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. Circulation: Arrhythmia and Electrophysiology, 2018, 11, e005593.	2.1	17
151	Use of a Coronary Sinus Lead and Biventricular ICD to Correct a Sensing Abnormality in a Patient with Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. Journal of Cardiovascular Electrophysiology, 2006, 17, 317-320.	0.8	15
152	Identification of sarcomeric variants in probands with a clinical diagnosis of arrhythmogenic right ventricular cardiomyopathy (ARVC). Journal of Cardiovascular Electrophysiology, 2018, 29, 1004-1009.	0.8	15
153	Safety and Utility of Cardiopulmonary Exercise Testing in Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia. Journal of the American Heart Association, 2020, 9, e013695.	1.6	14
154	Translational Research on the Mitral Valve: from Developmental Mechanisms to New Therapies. Journal of Cardiovascular Translational Research, 2011, 4, 699-701.	1.1	13
155	Optimization of Serum Immunoglobulin Free Light Chain Analysis for Subclassification of Cardiac Amyloidosis. Journal of Cardiovascular Translational Research, 2015, 8, 264-268.	1.1	13
156	Comprehensive Versus Targeted Genetic Testing in Children with Hypertrophic Cardiomyopathy. Pediatric Cardiology, 2016, 37, 845-851.	0.6	13
157	The Role of Genetics in Peripartum Cardiomyopathy. Journal of Cardiovascular Translational Research, 2017, 10, 437-445.	1.1	13
158	Characterization of microsatellite markers flankingFBN1: Utility in the diagnostic evaluation for Marfan syndrome. American Journal of Medical Genetics Part A, 2001, 99, 39-47.	2.4	12
159	Baseline Characteristics Predict the Presence of Amyloid on Endomyocardial Biopsy. Journal of Cardiac Failure, 2017, 23, 340-344.	0.7	12
160	SSRI/SNRI Therapy is Associated With a Higher Risk of Gastrointestinal Bleeding in LVAD Patients. Heart Lung and Circulation, 2020, 29, 1241-1246.	0.2	12
161	Managing Secondary Genomic Findings Associated With Arrhythmogenic Right Ventricular Cardiomyopathy. Circulation Genomic and Precision Medicine, 2018, 11, e002237.	1.6	11
162	Genetic aetiologies should be considered in paediatric cases of acute heart failure presumed to be myocarditis. Cardiology in the Young, 2019, 29, 917-921.	0.4	11

#	Article	IF	Citations
163	Fluctuating creatinine in the cardiac unit. Clinica Chimica Acta, 2015, 447, 52-54.	0.5	10
164	Management of heart failure in cardiac amyloidosis using an ambulatory diuresis clinic. American Heart Journal, 2021, 233, 122-131.	1.2	10
165	A family with a complex clinical presentation characterized by arrhythmogenic right ventricular dysplasia/cardiomyopathy and features of branchioâ€oculoâ€facial syndrome. American Journal of Medical Genetics, Part A, 2013, 161, 371-376.	0.7	9
166	Targeted Mybpc3 Knock-Out Mice with Cardiac Hypertrophy Exhibit Structural Mitral Valve Abnormalities. Journal of Cardiovascular Development and Disease, 2015, 2, 48-65.	0.8	9
167	The prevalent I686T human variant and loss-of-function mutations in the cardiomyocyte-specific kinase gene TNNI3K cause adverse contractility and concentric remodeling in mice. Human Molecular Genetics, 2021, 29, 3504-3515.	1.4	9
168	Reader- and Instrument-Dependent Variability in the Electrocardiographic Assessment of Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. Journal of Cardiovascular Electrophysiology, 2011, 22, 561-568.	0.8	8
169	A pragmatic implementation research study for In Our DNA SC: a protocol to identify multi-level factors that support the implementation of a population-wide genomic screening initiative in diverse populations. Implementation Science Communications, 2022, 3, 48.	0.8	8
170	The Complex Genetics of Atrial Fibrillation. Journal of the American College of Cardiology, 2012, 60, 1182-1184.	1.2	7
171	The response to cardiac resynchronization therapy in <scp>LMNA</scp> cardiomyopathy. European Journal of Heart Failure, 2022, 24, 685-693.	2.9	7
172	Use of Genetics in the Clinical Evaluation and Management of Heart Failure. Current Treatment Options in Cardiovascular Medicine, 2010, 12, 566-577.	0.4	6
173	A Clinical Approach to a Family History of Sudden Death. Circulation: Cardiovascular Genetics, 2012, 5, 697-705.	5.1	6
174	Extensive Cardiac Allograft Vasculitis and Concurrent Fat Necrosis 6 Years After Orthotopic Heart Transplantation. Journal of Heart and Lung Transplantation, 2007, 26, 1212-1216.	0.3	5
175	Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. Circulation, 2011, 123, 2661-2663.	1.6	4
176	Case Report of a Patient with Left Ventricular Assistance Device Undergoing Chemotherapy for a New Diagnosis of Lung Cancer. Case Reports in Oncological Medicine, 2015, 2015, 1-3.	0.2	4
177	Review and Updates in Regenerative and Personalized Medicine, Preclinical Animal Models, and Clinical Care in Cardiovascular Medicine. Journal of Cardiovascular Translational Research, 2015, 8, 466-474.	1.1	4
178	Bringing Autopsies Into the Molecular Genetic Era. Circulation, 2018, 137, 2727-2729.	1.6	4
179	Clinical pathway to screen for cardiac amyloidosis in heart failure with preserved ejection fraction. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 166-167.	1.4	4
180	Influence of Panel Selection on Yield of Clinically Useful Variants in Arrhythmogenic Right Ventricular Cardiomyopathy Families. Circulation Genomic and Precision Medicine, 2020, 13, 548-550.	1.6	4

#	Article	IF	Citations
181	Genetic Dilated Cardiomyopathy Due to TTN Variants Without Known Familial Disease. Circulation Genomic and Precision Medicine, 2020, 13, e003082.	1.6	4
182	Familial Amyloid Cardiomyopathy Due to TTR Mutations: An underground Cause of Restrictive Cardiomyopathy. Journal of Cardiac Failure, 2009, 15, 464.	0.7	3
183	Phenotypic diversity arising from a single mutation. Heart Rhythm, 2009, 6, 1584-1585.	0.3	3
184	Advances in Induced Pluripotent Stem Cells, Genomics, Biomarkers, and Antiplatelet Therapy Highlights of the Year in JCTR 2013. Journal of Cardiovascular Translational Research, 2014, 7, 518-525.	1.1	3
185	Absence of a Primary Role for SCN10A Mutations in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. Journal of Cardiovascular Translational Research, 2016, 9, 87-89.	1.1	3
186	Giant Ring Mitochondria in a Patient With Heart Failure and Cerebral White Matter Disease Resulting From an MT-TL1 Mitochondrial Gene Mutation. Journal of Cardiac Failure, 2017, 23, 652-655.	0.7	3
187	Surgical correction of tricuspid regurgitation in patients with ARVD/C. HeartRhythm Case Reports, 2015, 1, 326-330.	0.2	2
188	Untangling Wild-Type TransthyretinÂAmyloidosis. Journal of the American College of Cardiology, 2016, 68, 1021-1023.	1.2	2
189	No major role for rare plectin variants in arrhythmogenic right ventricular cardiomyopathy. PLoS ONE, 2018, 13, e0203078.	1.1	2
190	Positive family history decreases diagnosis time by over 200%. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 17-17.	1.4	2
191	Wild-Type Transthyretin Cardiac Amyloidosis Is Associated with Increased Antecedent Physical Activity. Journal of Cardiovascular Translational Research, 2022, 15, 689-691.	1.1	2
192	Heart Failure and Genomics. Journal of the American College of Cardiology, 2007, 49, 1106.	1.2	1
193	Response to Letters Regarding Article, â€œElectrocardiographic Features of Arrhythmogenic Right Ventricular Dysplasiaâ€• Circulation, 2010, 121, .	1.6	1
194	Cardiovascular genetics provides new insights for early onset arrhythmogenic right ventricular dysplasia/cardiomyopathy. Heart Rhythm, 2011, 8, 1696-1697.	0.3	1
195	Cardiovascular Disease in Osteogenesis Imperfecta. , 2014, , 329-334.		1
196	Translating Cardiovascular Knowledge: A Global Health Perspective. Journal of Cardiovascular Translational Research, 2015, 8, 1-2.	1.1	1
197	Further Evidence of Harm From Exercise inÂARVD/C. Journal of the American College of Cardiology, 2015, 65, 1451-1453.	1.2	1
198	Intracardiac Giant Cells After Left Ventricular Assist Device Placement. Journal of Heart and Lung Transplantation, 2007, 26, 417-420.	0.3	0

#	Article	IF	Citations
199	E713K in desmoglein-2 and arrhythmogenic right ventricular dysplasia/cardiomyopathy. Nature Clinical Practice Cardiovascular Medicine, 2008, 5, E2-E2.	3.3	0
200	One step closer to personalized genomic medicine. European Heart Journal, 2010, 31, 2194-2196.	1.0	0
201	Why Should Cardiologists Consider Genetic Testing for Hypertrophic Cardiomyopathy? â^—. JACC: Heart Failure, 2015, 3, 189-191.	1.9	0
202	GLA-Ring Opportunities and Challenges for Fabry Disease â^—. Journal of the American College of Cardiology, 2016, 68, 2564-2566.	1.2	0
203	Inheritance Impacts Mitral Valve Insufficiency. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	0
204	Four-Chamber Intracardiac Thrombi Complicating Wild-Type TTR Amyloidosis. Case Reports in Cardiology, 2018, 2018, 1-4.	0.1	0
205	Heart Failure as a Consequence of Genetic Cardiomyopathy. , 2020, , 322-332.e2.		0
206	Abstract 18850: A Report on Cardiomyopathy and Arrhythmia Incidence in a Duchenne Muscular Dystrophy Cohort. Circulation, 2015, 132, .	1.6	0
207	Multivalvular Pulsus Alternans. Circulation: Heart Failure, 2020, 13, e007134.	1.6	0
208	Cardiac Amyloidosis. , 2020, , 167-177.		0
209	How did transthyretin amyloid cardiomyopathy progress in patients who took placebo in the study ATTR-ACT? A plain language summary. Future Cardiology, 2022, , .	0.5	0
210	Abstract 24032: Exercise Instigates Apoptosis-inducing Factor Nuclear Translocation and Myocyte Death in Arrhythmogenic Cardiomyopathy. Circulation, 2017, 136, .	1.6	0